The impact of intense exercise on uptake and excresion of glucocorticoides in relation to doping analysis

Impact of intense exercise on pharmacokinetics of glucocorticoides in relation to doping analysis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2014-005186-73-DK

Enrollment

Registered

2015-01-13

Start date

2015-03-18

Completion date

Unknown

Last updated

2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Impact of intense exercise on pharmacokinetics of glucocorticoids in relation to doping analysis

Interventions

Trade Name: Medrol Product Name: Medrol Pharmaceutical Form: Tablet INN or Proposed INN: Methylprednisolone Other descriptive name: METHYLPREDNISOLONE Concentration unit: mg milligram(s) Concentration

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Males between 18 and 40 years (both included) Physically active at least 5 hours a week VO2-max at least 55 ml/min/kg Non smoker No daily use of medication Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 24 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Hypersensitivity towards the active substance or any one of the other substances within the medicine Coronary heart disease, asthma or other cronical disease Not abe to get doctors permission to participate in the trials after an objective test

Design outcomes

Primary

Measure	Time frame
Main Objective: Determine the impact of intense training on pharmacological properties of glucocorticoids;Secondary Objective: Not applicable;Primary end point(s): Urine concentration of glucocorticoids ;Timepoint(s) of evaluation of this end point: The end point will be evaluated in autumn 2017	—

Secondary

Measure	Time frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable	—

Countries

Denmark

Contacts

Public ContactVibeke Backer

Bispebjerg University Hospital

mortenhostrup@gmail.com

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026